TAsmanian Study of Echocardiographic detection of Left ventricular dysfunction (TAS-ELF)

Not Applicable

Recruiting

• Conditions: Heart failure; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12614000080628
• Lead Sponsor: Menzies Research Institute Tasmania

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-01-22
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 800

Inclusion Criteria

Aged >65 years with one or more of the following;
- diabetes (T2DM)
- obesity
- high blood pressure
- past cancer chemotherapy
- F/H of heart failure
- known cardiac disease (but not existing heart failure)

Exclusion Criteria

- Unable to provide written informed consent to participate in this study
- Participating in another clinical research trial where randomized treatment would be unacceptable
- History of >moderate valvular heart disease
- History of previous heart failure
- Existing medical therapy with beta blockers and ACE inhibitors
- Contraindications/Intolerance to beta blockers or ACE inhibitors
- Systolic BP <110mmHg
- Pulse <60/minute
- Baseline NYHA >2
- Oncologic life expectancy < 12 months
- Inability to acquire interpretable images (identified from baseline echo)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ew heart failure (HF) or LV dysfunction. This will be assessed on the basis of clinical diagnosis of HF. LV dysfunctiuon will be defined on the basis of 3D echo.[24 months after the initial screening study]

Secondary Outcome Measures

Name	Time	Method
Cardiovascular fitness, assessed using 6-minute walk test[24 months after the initial screening study]